Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20730298 | 0.92 | CYP4F2 (0.46) | CYP4A11CYP4F2GAATDP1POLB | |
| SCHEMBL355529 | 0.88 | TSHR (0.38) | CYP4A11CYP4F2DGAT1TSHR | |
| SCHEMBL13080893 | 0.84 | TSHR (0.40) | TSHR | |
| SCHEMBL16869115 | 0.82 | ALDH1A1 (0.44) | CYP4A11CYP4F2DGAT1TSHR | |
| SCHEMBL15026699 | 0.82 | TDP1 (0.41) | CYP4A11CYP4F2GAATDP1DGAT1 | |
| SCHEMBL17574066 | 0.80 | DGAT1 (0.42) | GAADGAT1TSHR | |
| SCHEMBL10682128 | 0.79 | DGAT1 (0.35) | DGAT1TSHR | |
| SCHEMBL15012918 | 0.79 | CYP4F2 (0.40) | CYP4A11CYP4F2GAATDP1DGAT1 | |
| SCHEMBL2183590 | 0.79 | DGAT1 (0.35) | DGAT1TSHR | |
| SCHEMBL14090739 | 0.78 | PAOX (0.38) | CYP4A11CYP4F2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2024054845-A1 | MACROCYCIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | CYP4A11 594/4885CYP4F2 1256/4885GAA 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.